Loading...
XSHG
603520
Market cap673mUSD
Jul 30, Last price  
11.05CNY
1D
-2.47%
1Q
31.24%
Jan 2017
-36.71%
IPO
57.41%
Name

Zhejiang Starry Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
P/E
109.52
P/S
2.21
EPS
0.10
Div Yield, %
0.45%
Shrs. gr., 5y
0.74%
Rev. gr., 5y
19.78%
Revenues
2.20b
+3.04%
506,582,117574,710,788685,904,772658,482,615695,660,000672,945,253710,939,018890,470,7811,308,841,6351,367,087,2411,999,916,8882,131,239,9882,195,986,154
Net income
44m
67,567,06535,784,63663,657,74467,704,20868,944,11876,121,53983,116,97493,676,375170,331,965238,729,340323,754,754044,232,089
CFO
46m
-41,072,600103,342,43174,993,069144,000,55994,879,3667,679,73418,104,512191,835,586246,768,072174,479,180508,839,385046,126,089
Dividend
Sep 09, 20240.05 CNY/sh

Profile

Zhejiang Starry Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of X-CT non-ionic contrast agents and fluoroquinolones drugs and intermediates in China and internationally. Its contrast agent products include iohexol, iohexol hydrolysate, iohexol iodide, ioversol, iopamidol, iomeprol, iopromide, cybeclamine, iodixanol, gadopentetic acid dimeglumine, and glutamate; and fluoroquinolones products comprise levofloxacin, levofloxacin hydrochloride, levoflurane, levofluorocarboxylic acid, pazufloxacin, and pazufloxacin mesylate. The company was founded in 1997 and is based in Xianju, China.
IPO date
Mar 09, 2016
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,195,986
3.04%
2,131,240
6.57%
Cost of revenue
1,939,744
1,891,012
Unusual Expense (Income)
NOPBT
256,242
240,228
NOPBT Margin
11.67%
11.27%
Operating Taxes
799
6,521
Tax Rate
0.31%
2.71%
NOPAT
255,443
233,707
Net income
44,232
 
Dividends
(68,251)
(122,438)
Dividend yield
1.42%
1.83%
Proceeds from repurchase of equity
(10,183)
BB yield
0.21%
Debt
Debt current
1,855,028
2,106,641
Long-term debt
734,480
676,929
Deferred revenue
94,410
Other long-term liabilities
91,665
1
Net debt
1,894,932
1,986,069
Cash flow
Cash from operating activities
46,126
CAPEX
(266,225)
Cash from investing activities
(255,560)
Cash from financing activities
83,011
363,584
FCF
252,969
(529,464)
Balance
Cash
565,157
662,440
Long term investments
129,418
135,061
Excess cash
584,776
690,939
Stockholders' equity
806,055
994,327
Invested Capital
3,855,281
3,948,958
ROIC
6.55%
6.46%
ROCE
5.77%
5.18%
EV
Common stock shares outstanding
340,247
342,252
Price
14.08
-28.05%
19.57
-57.85%
Market cap
4,790,676
-28.47%
6,697,864
-57.81%
EV
6,691,903
8,689,907
EBITDA
435,796
400,670
EV/EBITDA
15.36
21.69
Interest
108,653
92,600
Interest/NOPBT
42.40%
38.55%